Volume 17, Number 3—March 2011
Dispatch
Molecular Epidemiology of Mycobacterium tuberculosis, Buenos Aires, Argentina
Ximena Gonzalo
, Marta Ambroggi, Ezequiel Cordova, Tim Brown, Susana Poggi, and Francis Drobniewski
, Marta Ambroggi, Ezequiel Cordova, Tim Brown, Susana Poggi, and Francis Drobniewski
Appendix
Table. Drug susceptibility profiles for 57 patients with MDR TB, Buenos Aires, Argentina, June 1, 2006–April 30, 2007*
| Patient no. | INH | Rif | P | E | Str | PAS | Cs | Pto | Eto | Cm | Am | Km | Cip | Ofx | Lfx | Mfx |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | R | R | S | S | R | S | S | – | – | – | – | S | – | – | – | – |
| 2 | R | R | R | – | R | – | – | – | S | – | – | – | – | – | – | – |
| 3 | R | R | S | S | R | S | – | – | – | – | – | S | – | – | – | – |
| 4 | R | R | R | R | R | S | S | – | – | – | – | R | – | R | – | – |
| 5 | R | R | R | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 6 | R | R | R | R | R | R | S | – | – | S | – | R | – | S | – | S |
| 7 | R | R | – | R | R | – | – | – | – | – | – | – | – | – | – | – |
| 8 | R | R | R | S | R | S | S | – | – | – | – | R | – | – | – | – |
| 9 | R | R | – | S | R | S | S | – | – | – | – | – | – | – | – | – |
| 10 | R | R | R | R | R | – | – | – | – | – | R | – | – | – | – | – |
| 11 | R | R | R | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 12 | R | R | R | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 13 | R | R | R | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 14 | R | R | S | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 15 | R | R | R | R | R | S | S | S | S | R | R | R | – | S | – | S |
| 16 | R | R | R | R | R | – | – | S | S | R | R | R | – | S | – | S |
| 17 | R | R | R | R | R | S | S | – | – | – | – | R | – | – | – | – |
| 18 | R | R | R | R | R | S | S | S | R | R | R | R | – | S | – | S |
| 19 | R | R | R | R | R | S | S | S | S | R | R | R | S | S | – | S |
| 20 | R | R | R | S | R | S | – | S | S | R | R | R | – | S | – | S |
| 21 | R | R | R | R | R | – | – | S | S | R | R | R | S | S | – | S |
| 22 | R | R | R | R | S | S | – | – | – | – | – | R | – | – | – | – |
| 23 | R | R | R | R | R | – | – | – | – | R | R | R | – | R | – | R |
| 24 | R | R | R | R | R | S | R | R | R | S | S | R | – | S | – | S |
| 25 | R | R | S | R | R | S | S | – | – | – | – | S | – | – | – | – |
| 26 | R | R | R | R | R | S | S | – | – | – | – | – | – | – | – | – |
| 27 | R | R | R | R | R | R | S | – | – | – | – | R | – | R | – | – |
| 28 | R | R | R | R | R | R | S | – | – | – | – | R | – | S | – | – |
| 29 | R | R | R | – | S | S | S | – | – | – | – | – | – | – | – | – |
| 30 | R | R | R | S | S | S | S | – | – | – | – | S | – | – | – | – |
| 31 | R | R | S | S | R | S | S | – | – | – | – | S | – | – | – | – |
| 32 | R | R | S | S | R | S | S | – | – | – | – | S | – | – | – | – |
| 33 | R | R | R | R | S | S | – | – | – | – | – | S | – | – | – | – |
| 34 | R | R | – | S | R | S | – | – | – | – | – | – | – | – | – | – |
| 35 | R | R | R | R | S | S | S | – | – | – | – | S | – | S | – | – |
| 36 | R | R | S | R | S | S | S | – | – | – | – | – | – | – | – | – |
| 37 | R | R | S | S | S | S | – | – | – | – | – | – | – | – | – | – |
| 38 | R | R | R | S | S | S | S | – | – | – | – | S | – | – | – | – |
| 39 | R | R | R | R | R | S | S | – | – | – | R | R | – | R | – | – |
| 40 | R | R | S | R | R | S | S | – | – | S | – | S | – | S | – | – |
| 41 | R | R | R | R | S | S | S | – | – | – | – | S | – | – | – | – |
| 42 | R | R | – | R | R | S | S | – | – | – | – | R | – | – | – | – |
| 43 | R | R | – | S | S | S | – | S | R | S | S | S | – | S | – | S |
| 44 | R | R | R | R | R | R | S | – | – | – | – | – | – | S | – | – |
| 45 | R | R | R | R | R | S | S | – | – | – | – | R | – | – | – | – |
| 46 | R | R | R | R | R | S | S | – | – | – | – | R | – | – | – | – |
| 47 | R | R | S | S | R | S | – | – | – | – | – | S | – | – | – | – |
| 48 | R | R | R | S | S | S | – | – | – | – | – | – | – | – | – | – |
| 49 | R | R | S | S | R | S | S | – | – | – | – | S | – | – | – | – |
| 50 | R | R | R | R | R | R | R | – | – | S | – | R | R | R | – | S |
| 51 | R | R | S | R | S | S | – | – | – | – | – | – | – | – | – | – |
| 52 | R | R | S | S | S | S | S | – | – | – | – | – | – | – | – | – |
| 53 | R | R | R | S | S | S | – | R | R | – | – | S | – | S | – | – |
| 54 | R | R | R | R | R | S | S | – | – | – | – | R | – | – | – | – |
| 55 | R | R | – | S | S | – | – | – | – | – | – | – | – | – | – | – |
| 56 | R | R | – | S | S | S | S | – | – | – | – | S | – | – | – | – |
| 57 | R | R | S | R | R | S | S | – | – | – | – | S | – | – | – | – |
*MDR, multidrug resistant; TB, tuberculosis; INH, isoniazid; Rif, rifampicin; P, pyrazinamide; E, ethambutol; Str, streptomycin; PAS, p-aminosalicylic acid; Cs, cycloserine; Pto, proteonamide; Eto, ethionamide; Cm, capreomycin; Am, amikacin; Km, kanamycin; Cip, ciprofloxacin; Ofx, ofloxacin; Lfx, levofloxacin; Mfx, moxifloxacin; R, resistant; S, susceptible; –, drugs not tested for those strains.
Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.